Articles

Initiating inflammasome inhibitor development

ZyVersa Therapeutics to advance development of its lead inflammasome inhibitor with Selexis and KBI Biopharma’s integrated development platform
Brought to you byDDNews Staff
| 2 min read

GENEVA & DURHAM, N.C.—Selexis SA and KBI Biopharma, Inc. have announced a new collaboration with ZyVersa Therapeutics to advance development of ZyVersa’s lead inflammasome inhibitor, IC 100, for the treatment of multiple inflammatory conditions.

Under the collaboration, ZyVersa will use Selexis’ innovative cell line expression technologies in combination with KBI Biopharma’s contract development manufacturing services to advance IC 100 into the clinic. The collaboration includes a commercial license agreement between Selexis and IC 100’s licensor, InflamaCORE, LLC.

To continue reading this article, subscribe for FREE toDrug Discovery News Logo

Subscribe today to keep up to date with the latest advancements and discoveries in drug development achieved by scientists in pharma, biotech, non-profit, academic, clinical, and government labs.

Add Drug Discovery News as a preferred source on Google

Add Drug Discovery News as a preferred Google source to see more of our trusted coverage.

Here are some related topics that may interest you:

Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Gloved hand holding a multiwell cell culture plate under a fluorescence microscope for spheroid analysis.
Using confocal live-cell imaging to characterize immune-mediated cytotoxicity over time.
Fluorescence microscopy image of cells displaying green and red fluorescent signals.
Using confocal live-cell imaging to assess treatment effects in spheroids, organoids, and co-cultures.
3D illustration of Y-shaped antibody molecules floating against a soft blue background, with a detailed antibody structure in the foreground.
From molecular developability to functional activity, integrated characterization strategies help inform lead selection and optimization in biologics discovery.